Cogstate Ltd (ASX: CGS) Share Price and News

Mr Myer previously served as Deputy Chancellor of the Council of the University of Melbourne, President of The Myer Foundation, one of two principle Myer Family philanthropic funds, President of the Howard Florey Institute of Experimental Physiology and Medicine and was a director of The Florey Institute of Neuroscience and Mental Health, where he participated in the transition of the Institute's research focus towards diagnostic and therapeutic neuroscience, including a focus on degenerative brain diseases.

Mr O'Connor has responsibility for Cogstate's overall strategic direction and day-to-day operations as well as development of expansion opportunities outside of the core clinical trials business. Prior to that, Mr O'Connor held senior positions at Spherion Group, Australian Wine Exchange and PricewaterhouseCoopers.

Mr Inns has more than 30 years has experience in finance, accounting and executive leadership. He has held senior executive roles with Uniti Group Limited, M2 Group Limited, Vocus Limited and iSelect Limited. Mr Inns brings governance, risk and compliance experience, with regular engagement at Board and Audit & Risk Committee level across highly regulated industries, and service as a director on subsidiary and trustee boards. He has an investor relations background, presenting to investors and analysts across varied market conditions, and has led digital transformation initiatives, including group-wide ERP and finance system implementations to improve transparency and Board reporting. He is a member of the Risk and compliance committee.

Ms Player brings healthcare experience and commercial expertise to the Board of Cogstate. She has held senior executive roles with Healthscope Ltd, a private healthcare provider in Australia, including the former positions of Group Executive - Legal, Governance and Sustainability, and General Counsel and Company Secretary from 2005 until 2019. Ms Player also has international commercial and regulatory experience that spans different markets and industries, which she obtained in private legal practice in Australia and in The Netherlands. She is Chair of the Risk and compliance committee.

Dr Mohs is currently Chief Scientific Officer for the Global Alzheimer's Platform (GAP) Foundation, a non- profit devoted to enhancing Alzheimer's disease research. Richard also serves as a consultant to academic institutions, foundations and biopharmaceutical companies, and is a member of the Board of Governors for the Alzheimer's Drug Discovery Foundation. Dr Mohs retired from Eli Lilly in 2015, where he held leadership positions including Vice President for Neuroscience Early Clinical Development and Leader of the Global Alzheimer's Drug Development Team. Before joining Eli Lilly, Dr Mohs spent 23 years with the Mount Sinai School of Medicine where he was Professor in the Department of Psychiatry and Associate Chief of Staff for Research at the Bronx Veterans Affairs Medical Centre.

Ms Wenn is an experienced board director who has brought technology experience and commercial expertise to the Board of Cogstate, with over 30 years of experience in innovation roles. Kim's experience includes, among other things, business strategy, governance and change management-with a focus on digital disruption. She is a member of the Risk and compliance committee.

-

-

-

-

-

-